Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Avantor Inc. (AVTR) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Medical Instruments & Supplies
$8.31
+0.00 (0.00%)Did AVTR Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Avantor is one of their latest high-conviction picks.
Based on our analysis of 33 Wall Street analysts, AVTR has a neutral consensus with a median price target of $9.00 (ranging from $7.00 to $19.00). The overall analyst rating is Buy (6.4/10). Currently trading at $8.31, the median forecast implies a 8.3% upside. This outlook is supported by 3 Buy, 10 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 15.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for AVTR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2026 | Citigroup | Patrick Donnelly | Neutral | Maintains | $9.00 |
| Apr 30, 2026 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $8.00 |
| Apr 15, 2026 | Barclays | Luke Sergott | Underweight | Maintains | $7.00 |
| Apr 6, 2026 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $8.50 |
| Mar 6, 2026 | Barclays | Luke Sergott | Underweight | Downgrade | $8.50 |
| Feb 13, 2026 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $14.00 |
| Feb 12, 2026 | Citigroup | Patrick Donnelly | Neutral | Maintains | $11.00 |
| Feb 12, 2026 | Barclays | Luke Sergott | Equal-Weight | Maintains | $9.00 |
| Jan 7, 2026 | TD Cowen | Dan Brennan | Hold | Maintains | $12.00 |
| Jan 5, 2026 | Evercore ISI Group | Vijay Kumar | In-Line | Downgrade | $12.00 |
| Dec 17, 2025 | Jefferies | Tycho Peterson | Underperform | Downgrade | $9.00 |
| Oct 30, 2025 | JP Morgan | Casey Woodring | Neutral | Downgrade | $12.00 |
| Oct 30, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $14.00 |
| Oct 30, 2025 | Barclays | Luke Sergott | Equal-Weight | Downgrade | $12.00 |
| Oct 24, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $17.00 |
| Oct 16, 2025 | Raymond James | Andrew Cooper | Outperform | Maintains | $16.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $15.00 |
| Aug 4, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $12.00 |
| Aug 4, 2025 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $14.00 |
| Aug 4, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $16.00 |
The following stocks are similar to Avantor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Avantor Inc. has a market capitalization of $5.67B with a P/E ratio of 14.9x. The company generates $6.55B in trailing twelve-month revenue with a -8.4% profit margin.
Revenue growth is -4.9% quarter-over-quarter, while maintaining an operating margin of +6.3% and return on equity of -9.4%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Provides essential products and services for life sciences.
Avantor generates revenue by offering a wide range of mission-critical products and services, including laboratory chemicals, consumables, equipment, and instrumentation. Its business model focuses on serving customers in various sectors such as life sciences, advanced technologies, and applied materials, ensuring consistent demand for its offerings.
Operating in over 30 countries, Avantor has a diverse client base that includes pharmaceutical and biotechnology companies, academic institutions, and government entities. The company's commitment to sustainability and compliance enhances its reputation and positions it as a leader in the scientific supply sector.
Healthcare
Medical Instruments & Supplies
13,500
Mr. Michael Stubblefield
United States
2019
AVTR benefits from stable Q1 revenues and improving demand trends, though margin pressure and volume softness weigh on profitability.
Avantor, Inc. (AVTR) held its Q1 2026 earnings call, providing insights into its financial performance and strategic initiatives for the quarter. Further details can be found in the transcript.
The Q1 2026 earnings call for Avantor, Inc. provides insights into the companyโs financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but faces pressure from negative organic growth and margin compression, indicating early stabilization, not recovery. 2026 guidance reaffirmed.
Avantor's mixed earnings report highlights ongoing challenges in growth and margins, signaling cautious recovery prospects, which may affect investor sentiment and stock performance.
Avantor, Inc. reported Q1 2026 net sales of $1.581 billion, net income of $43 million, adjusted EBITDA of $219 million, and reaffirmed FY 2026 guidance.
Strong sales and positive adjusted earnings indicate solid performance, while reaffirming guidance suggests stability. Positive cash flow metrics enhance confidence in the company's financial health.
Avantor, Inc. (AVTR) reported Q3 earnings of $0.17 per share, surpassing the Zacks estimate of $0.16, but down from $0.23 per share in the same quarter last year.
Avantor's earnings beat expectations, indicating strong performance, but the year-over-year decline signals potential challenges ahead, affecting investor sentiment and stock valuation.
AVTR reported stable Q1 revenues with improving demand trends, but faces margin pressure and volume softness affecting profitability.
Stable Q1 revenues and improving demand signal potential growth for AVTR, but margin pressure and soft volumes could hinder profitability, affecting future performance and investment decisions.
Kuehn Law is investigating potential breaches of fiduciary duties by Avantor, Inc. officers and directors, which may impact shareholder interests.
The investigation into Avantor's officers and directors may signal potential legal troubles, affecting the company's stock price and investor confidence.
Based on our analysis of 33 Wall Street analysts, Avantor Inc. (AVTR) has a median price target of $9.00. The highest price target is $19.00 and the lowest is $7.00.
According to current analyst ratings, AVTR has 3 Buy ratings, 10 Hold ratings, and 2 Sell ratings. The stock is currently trading at $8.31. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict AVTR stock could reach $9.00 in the next 12 months. This represents a 8.3% increase from the current price of $8.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
Avantor generates revenue by offering a wide range of mission-critical products and services, including laboratory chemicals, consumables, equipment, and instrumentation. Its business model focuses on serving customers in various sectors such as life sciences, advanced technologies, and applied materials, ensuring consistent demand for its offerings.
Price targets from Wall Street analysts for AVTR are not currently available. The stock is trading at $8.31.
The lowest price target for AVTR is $7.00 from Luke Sergott at Barclays, which represents a -15.8% decrease from the current price of $8.31.
The overall analyst consensus for AVTR is neutral. Out of 33 Wall Street analysts, 3 rate it as Buy, 10 as Hold, and 2 as Sell, with a median price target of $9.00.
Stock price projections, including those for Avantor Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.